
|Articles|September 10, 2003
Bisphosphonate shown to slow bone loss in advanced prostate cancer patients
An oral bisphosphonate may slow the development of symptomatic bone metastases and reduce the risk of death from this disease, new data show.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











